相关实验视频

Updated: Sep 19, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

CD302预测慢性髓性白血病患者的深度分子响应的实现,这些患者接受了伊马替尼布治疗

Chung Hoow Kok^1,2,3,4, Yazad Irani^1,2, Jade Clarson¹

¹Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, Australia.

Blood neoplasia

|June 2, 2025

概括

研究人员使用CD基因表达和临床数据确定了慢性髓性白血病 (CML) 患者不太可能达到深度分子响应 (DMR). 高3个月BCR::ABL1%或CD302表达确定了低风险群体,具有明显较低的DMR率.

科学领域:

血液学血液学血液学
分子生物学分子生物学
基因组学就是基因组学.

背景情况:

深度分子响应 (DMR) 对于慢性髓性白血病 (CML) 的无治疗缓解至关重要.
预测不太可能达到持续的DMR的患者对于优化CML治疗策略至关重要.
目前的预后标记可能无法完全捕捉所有患有DMR失败风险的患者.

研究的目的:

确定新的生物标志物,以预测CML患者在5年内实现DMR的可能性.
根据诊断时的分子和临床因素来区分预后不佳的患者子组.
探索与不良的DMR成就相关的潜在分子机制.

主要方法:

来自131名用伊马替尼或尼洛丁尼治疗的CML患者的外周血液样本的转录微阵列分析.
决策树分析以根据基因表达和临床变量识别不同的低风险 (PR) 队列.
基因组丰富分析,以调查已识别的风险组中的分子途径.

主要成果:

确定了两个低风险 (PR) 队列:PR-1 (高3个月BCR:ABL1%) 和PR-2 (高CD302表达).
这两个PR组的5年DMR实现率明显低于良好的风险 (GR) 组.
在PR-2中,细胞周期基因表达减少,新陈代谢和STAT3通路基因表达增加,与白血病细胞持久性有关.

结论:

高CD302表达是一种潜在的生物标志物,可以预测CML中DMR达到较低的水平.
在高CD302CML患者中准STAT3和代谢途径可能提供新的治疗策略.
改善DMR失败的预测可以指导CML管理的个性化治疗方法.

更多相关视频

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...